“Extraordinary Measures” - Hollywood Features the John Crowley Story

John Crowley, a featured Keynote at this year’s Molecular Medicine Tri-Conference, is the inspiration for a new film which will find its way onto the big screen January 22.

This moving story is truly a display of why your research efforts are so important. John Crowley, a successful entrepreneur and father who fought tirelessly to save the lives of his infant children from an incurable disease, is the inspiration for the movie. Extraordinary Measures, stars some of Hollywood's biggest names: Harrison Ford, Brendan Fraser, and Keri Russell. Read more

We look forward to hearing John speak and encourage you to see this film.

Just Announced Topic Lineup for 2010

Channel all your scientific energy into this year's exciting lineup of topics. CHI is proud to announce this year's event is built around 6 scientific channels providing attendees more learning opportunities than ever before. Featured channels include diagnostics, chemistry, informatics, biologics, cancer and executive. We're looking to provide attendees a more in depth experience into each of these six areas of research and development. Visit www.Tri-Conference.com and to view the updated topic list, as well as submit and abstract to present.

The Molecular Medicine Tri-Conference 2009 was a HUGE success. Molecular Medicine's leading researchers and executives came together.

Over 2700 Attendees
1179 Participating Companies
150 Exhibitors
Over 80 Posters
Representatives from Over 38 Countries

The Molecular Medicine Tri-Conference was referenced in multiple articles, social media groups and blogs. The following are just a few that we found.

http://weblog.josephcerro.com/2008/10/2009-molecular.html

http://blog.nextbio.com/2009/03/03/notes-from-the-molecular-medicine-tri-conferencetes/

www.bio-itworld.com/2009/02/26/tenenbaum-mmtc-keynote.html

www.bio-itworld.com/news/03/03/09/Merck-Sage-disease-biology.html

Attendees were also quite active tweeting about the event on Twitter.

Be sure to mark your calendars. Molecular Medicine Tri-Conference will be back in San Francisco, February 2-5, 2010 and CHI is already busy lining up next year's speaker list.

Continue to view Tri-Conference.com for all the latest event updates.

Pathway Knowledge Featured Upcoming Genetic Engineering News Article

The February 15 issue of Genetic Engineering News will feature an article on Pathway Knowledge Can Benefit Cancer Therapeutics, written by David Daniels. Please click here to read this timely article.

It is based on several talks illustrating how analytical methodologies show promise for identifying points for intervention. The Cancer Profiling and Pathways conference is coming up February 25-27 at the Molecular Medicine Tri-conference at the Moscone North Convention Center in San Francisco.

To learn more about this topic and view the agenda for the Fifth Annual Cancer Profiling and Pathways conference or visit www.Tri-Conference.com.

Insider Look at Modeling Sucesses

Renee Kenney and her team at Genstruct know how important modeling is. Using their causal network modeling (CNM) platform, they helped Sirtris Pharmaceuticals (acquired last year by GlaxoSmithKline for a cool $700 million) characterize several of their SIRT1 compounds. In only two months, Genstruct was able to model how two of the SIRT1 compounds worked and show that one compound in particular is much more potent at mimicking caloric restriction than resveratrol, an active ingredient in red wine.

Genstruct’s Causal Network Modeling platform is a unique approach to modeling and systems biology and the work won a Bio-IT World 2008 Best Practices award. Kenney is presenting the details of the project at a Best Practices Short Course at the Molecular Medicine Tri-Conference on February 24 (Short Course 6).

She and I talked a little about the teams' winning entry last month, and she gave me a preview of what she’ll be presenting in San Francisco. With successes like these under their belt, Genstruct is moving into modeling personalized medicine and is rumored to be working on a second Best Practices entry for the 2009 competition.

Dr. James A Wells - Releases Details on His Keynote Presentation "Engineering Cells to Death"

Apoptosis, or programmed cell death, represents an ultimate fate decision in cell biology. This process is critical for cellular differentiation and remodeling of tissues, and for anti-viral and anti-tumor defense. The study of apoptotic pathways has important ramifications for determining what is critical for cellular homeostasis, and for the development of potential anti-cancer therapeutics. A distinct molecular feature of apoptosis is the widespread but controlled cellular proteolysis, that is predominantly mediated by eight members of the caspase family of cysteine proteases. These enzymes are like demolition experts that cleave protein targets critical for cellular life. We have designed new enzymes, and antibodies, and small molecules to study and activate individual caspases and the proteins they cleave. For example, a robust proteomic method for global profiling of proteolysis (“degradomics”) in cells has been developed. Key to this is an engineered enzyme, subtiligase, that permits selective labeling and enrichment for the protein N-termini created as a result of proteolysis. Using this approach we have already identified >300 caspase substrates from Jurkat cells that were induced to undergo apoptosis by treatment with the chemotherapeutic agent etoposide. The proteins fall into a wide range of functional classes, and reveal much about the molecular components, logic, and timed sequence of events that drive a cell from life to death. We believe these engineered enzymes and proteomic approaches will be useful for characterizing the proteolysis of apoptosis induced by various agents or in different cell types, and will be generally useful for dissecting protease signaling pathways.

Bestselling author David Ewing Duncan takes the ultimate high-tech medical exam

Bestselling author David Ewing Duncan takes the ultimate high-tech medical exam, investigating the future impact of what's hidden deep inside all of us. David Ewing Duncan takes "guinea pig" journalism to the cutting edge of science, building on award-winning articles he wrote for Wired and National Geographic, in which he was tested for hundreds of chemicals and genes associated with disease, emotions, and other traits. Expanding on these tests, he examines his genes, environment, brain, and body, exploring what they reveal about his and his family's future health, traits, and ancestry, as well as the profound impact of this new self-knowledge on what it means to be human. David Ewing Duncan (San Francisco, CA) is the Chief Correspondent of public radio's Biotech Nation and a frequent commentator on NPR's Morning Edition. He is a contributing editor to Portfolio, Discover, and Wired and a columnist for Portfolio. His books include the international bestseller Calendar: Humanity's Epic Struggle to Determine a True and Accurate Year (978-0-380-79324-2). He is a former special producer and correspondent for ABC's Nightline, and appears regularly on CNN and programs such as Today and Good Morning America.

Don’t miss David Ewing Duncan’s Keynote this year's event on Thursday, February 26 at 2:25pm.